PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34360618-7	2021	In contrast, niclosamide, an inhibitor of TMEM16A, blocked mucus production and mucus secretion in vivo and in vitro.	Niclosamide	13-24	anoctamin 1, calcium activated chloride channel	Mus musculus	42-49	
35163010-5	2022	The potential of encapsulated niclosamide to inhibit TMEM16A whole-cell Cl- currents and intracellular Ca2+ signalling was assessed in airway epithelial cells in vitro.	Niclosamide	30-41	anoctamin 1, calcium activated chloride channel	Mus musculus	53-60	
32859916-6	2020	Knockout of Tmem16a or inhibition of TMEM16A in vivo by the FDA-approved drugs niclosamide and benzbromarone, as well as the TMEM16A-specific inhibitor Ani9 largely reduced cyst enlargement and abnormal cyst cell proliferation.	Niclosamide	79-90	anoctamin 1, calcium activated chloride channel	Mus musculus	12-19	
32859916-6	2020	Knockout of Tmem16a or inhibition of TMEM16A in vivo by the FDA-approved drugs niclosamide and benzbromarone, as well as the TMEM16A-specific inhibitor Ani9 largely reduced cyst enlargement and abnormal cyst cell proliferation.	Niclosamide	79-90	anoctamin 1, calcium activated chloride channel	Mus musculus	37-44	
31391337-4	2019	Here we demonstrate that the FDA-approved drug niclosamide, a potent inhibitor of TMEM16A identified by high-throughput screening, is an inhibitor of both TMEM16A and TMEM16F.	Niclosamide	47-58	anoctamin 1, calcium activated chloride channel	Mus musculus	82-89	
31391337-4	2019	Here we demonstrate that the FDA-approved drug niclosamide, a potent inhibitor of TMEM16A identified by high-throughput screening, is an inhibitor of both TMEM16A and TMEM16F.	Niclosamide	47-58	anoctamin 1, calcium activated chloride channel	Mus musculus	155-162	
31391337-7	2019	TMEM16A and TMEM16F support exocytic release of mucus and inflammatory mediators, both of which are blocked by niclosamide.	Niclosamide	111-122	anoctamin 1, calcium activated chloride channel	Mus musculus	0-7